Our data showed that SDL-1 induced STAT3 protein degradation while inhibiting the growth activity of gastric cancer cells in vitro, suggesting that it could be used as a potential anti-gastric cancer drug and providing a new strategy for gastric cancer therapy. Here, STAT3 is linked to gastric cancer.